Podcasts about aahivs

In this episode, a transfemme nonbinary individual living with HIV shares her experience navigating the healthcare system, alongside her infectious disease physician, Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS. Hear them discuss key considerations when caring for gender-diverse individuals, including: Understanding how people are more than just a diagnosis Prioritizing individuals' needs and providing whole-person care using shared decision-makingStrategies to make an environment more affirming and welcoming How to be an ally to transgender individualsListen to the individual in front of youHear what they're telling youMake sure they are being affirmed and seenLink to the full program:https://bit.ly/3AAOGpvGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this fascinating AJIC Science Into Practice episode, hosts Nikki and Jessica explore the crucial topic of post-exposure prophylaxis (PEP) with guest Dr. Carolyn Chu, Chief Clinical Officer of the National Clinician Consultation Center. They discuss the PEP line, a teleconsultation service supporting healthcare providers who manage exposures to bloodborne pathogens. The trio delves into the intricacies of PEP, the delay in its initiation, managing various exposures, and ensuring healthcare workers, particularly in urgent care, receive appropriate training and preparation to handle exposure properly and safely. With special guest: Carolyn Chu, MD, MSc, FAAFP, AAHIVS, Chief Clinical Officer/Principal Investigator of the National Clinician Consultation Center

In this episode, Jonathan Appelbaum, MD, FACP, AAHIVS, discusses the newest data supporting LA ART use in people with adherence challenges or viremia, including:The LATITUDE study, an open-label phase III study of LA CAB + RPV in people with a suboptimal response or nonadherence to oral ARTUpdates to the Ward 86 cohort, which showed 81% of patients with viral suppression on LA CAB + RPV at Week 48The CARES study, an open-label, noninferiority phase IIIb study of LA CAB + RPV in people with baseline resistance mutationsPresenter:Jonathan Appelbaum, MD, FACP, AAHIVSLaurie L. Dozier, Jr., MD Education Director and Professor of Internal MedicineChair, Department of Clinical SciencesFlorida State University College of MedicineMedical DirectorCare Point Health and WellnessTallahassee, FloridaLink to the full program:https://bit.ly/49x0W6DLink to the slideset: https://bit.ly/4bzZothTo get access to all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts or Spotify.  

In this episode, Jonathan Appelbaum, MD, FACP, AAHIVS, discusses the updated CDC guidance on how to monitor for HIV in people receiving PrEP, including:Rationale for why HIV monitoring differs for people receiving LA vs daily PrEPDescription of LEVI syndromeHow to transition a person from LA PrEP to HIV ART if they test positive for HIV Presenter:Jonathan Appelbaum, MD, FACP, AAHIVSLaurie L. Dozier, Jr., MD Education Director and Professor of Internal MedicineChair, Department of Clinical SciencesFlorida State University College of MedicineMedical DirectorCare Point Health and WellnessTallahassee, FloridaLink to the full program: https://bit.ly/49x0W6DLink to the slideset: https://bit.ly/4bzZothTo get access to all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.  

This is Ep. 1 of SHEA's two-part series, Impact of Blood Culture Practices on Antibiotic Stewardship & HAI Surveillance & Management. Speakers discuss effective preventive measures for reducing healthcare-onset bacteremia rates. Speakers: Mark Rupp, MD Anna Sick-Samuels, MD, MPH Moderator: Patricia Pichilingue-Reto, MD, FAAP, AAHIVS

Who doesn't want to live a better, healthier life? Basically, everyone desires it. However, challenges always stand in the way of achieving good health. In this episode, Dr. Tolulope Olabintan, owner and CEO of Livingspring Family Medical Center, shares her background as a family medicine and lifestyle medicine physician, emphasizing the significance of both quantity and quality of life in patient care. She also mentions the joy she finds in helping patients improve their well-being through weight loss and increased mobility. Additionally, she discusses the challenges people face in adopting healthier habits, including negative mindsets and beliefs that they are destined to follow their family's health history. Dr. Olabintan provides tips for living a healthier life, such as incorporating movement into daily routines, increasing fruit and vegetable intake, and minding one's thoughts to positively influence actions and decisions. Don't miss out on the insights that can transform your well-being. Tune in now for a healthier, happier you!    Episode Highlights: About Dr. Tolulope Olabintan Challenges people face in adopting a healthier lifestyle Tips for living a more healthier life Move Eat more fruits and vegetables Mind your mind Make water your drink of choice Get good sleep Active self care Prioritize taking care of your lives and making it a priority in the new year Connect with Dr. Tolulope Olabintan: Website | www.livingspringmedicals.com Clubhouse | @dr_olabintan Facebook | www.facebook.com/livingspringmedicals Instagram | @dr_olabintanmd Linked In | www.linkedin.com/in/tolulope-olabintan-md-faafp-dipabl Tiktok | @dr_olabintan Youtube| www.youtube.com/@dr.tolulopeolabintanmd62 About Dr. Tolulope Olabintan Dr. Tolulope Olabintan, MD, AAHIVS, FAAFP, DipABLM is a Board-Certified Family Physician, Board certified with American Board of Lifestyle Medicine, and a Fellow of the American Academy of Family Physicians. She also completed a Women's Health Fellowship and is a certified HIV specialist by the American Academy of HIV Medicine. She is fondly called by her patients as "Dr. O."  Dr. O is also the owner and CEO of Livingspring Family Medical Center, a primary care center located in Mansfield, Texas. She has over 13 years of medical experience. She helps patients live long and well as she believes the quantity of life is just as important as the quality of life. She places emphasis on lifestyle changes that help patients thrive throughout life. Furthermore, Dr. O is a life-enthusiast, a Christian, wife, and mom who enjoys good cuisine and can't get enough of the colors teal and orange.  Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

In this episode, Tavell L. Kindall, PhD, DNP, ARNP, FNP-BC, AACRN, AAHIVS, FAANP, and Anne Teitelman, PhD, FNP-BC, FANNP, FAAN, discuss key PrEP considerations for advanced practice providers in primary care settings, including: The importance of having PrEP navigators to help with logistics and be a point of contact for patients Where to find education and resources to familiarize yourself with PrEP and its prescribingSafety considerations and adverse events associated with PrEP optionsPrEP coverage and costHow to discontinue PrEP and the risk of resistance if someone acquires HIV while taking PrEPFacultyTavell L. Kindall, PhD, DNP, ARNP, FNP-BC, AACRN, AAHIVS, FAANPDirector, HIV Prevention and TreatmentSt. Thomas Community Health CenterNew Orleans, LouisianaAnne Teitelman, PhD, FNP-BC, FANNP, FAANAssociate Professor Emeritus of Nursing and Global Women's HealthDepartment of Family and Community HealthSchool of NursingUniversity of PennsylvaniaProfessorThomas Jefferson UniversityCollege of NursingPhiladelphia, PennsylvaniaLink to full program: https://bit.ly/3PZGYdR

In this episode, Dr Tavell Kindall and Jona Tanguay discuss actionable strategies for advanced practice providers to increase the frequency at which PrEP is offered and initiated in primary care settings. Topics covered include:Available training resources on how to offer PrEP in primary careAffordable, accessible PrEP options, including patient assistance programsUsing electronic health records to identify candidates for PrEPOpportunities to offer PrEP during appointments regarding birth control, STIs, or any other sexual health concernsHow to offer 3-site STI testing at your facilityWrapping PrEP into primary careIncorporating navigators or care coordinators to reduce logistical barriers and reach underserved populationsRapid testing, mobile testing, and Tele-PrEP as ways to facilitate PrEP initiation and simplify routine PrEP visitsHealthcare professionals' personal biases as a potential barrier to PrEPUsing ICD-10 codes for HIV PrEP as a way to further destigmatize PrEP and simplify billingFaculty:Tavell L. Kindall, PhD, DNP, ARNP, FNP-BC, AACRN, AAHIVS, FAANPDirector, HIV Prevention and TreatmentSt. Thomas Community Health CenterNew Orleans, LouisianaJona Tanguay, MMSc, PA-C, AAHIVSMedical Program Lead - Substance Use Disorders at Whitman-Walker HealthAssociate Medical Director - Transgender Health at Amida CarePresident-Elect at GLMA: Health Professionals Advancing LGBTQ+ EqualityClinical Instructor at Yale School of MedicineFounder at ChemsexHarmReduction.orgWashington, DCContent is supported by independent educational grants from Gilead Sciences, Inc. and ViiV Healthcare.Link to full program: https://bit.ly/3PZGYdR

Do you feel called to do something, but you've been ignoring it?Today I'm joined by my friend, Dr Tolu Olabintan, aka "Dr O" as her patients call her. Dr Olabintan is a fellow Family Medicine Physician and she shares her story of realizing that her overworking wasn't normal, and how her curiosity led her to not only discover how to let go of this tendency, but also to listen to her inner voice, calling her to create her own clinic. It's an inspiring story!Dr. Tolulope Olabintan, MD, AAHIVS, FAAFP, DipABLM is a Board-Certified Family Physician, Board certified with American Board of Lifestyle Medicine, and a Fellow of the American Academy of Family Physicians. She also completed a Women's Health Fellowship and is a certified HIV specialist by the American Academy of HIV Medicine. She is fondly called by her patients as "Dr. O."Dr. O is the Owner, Founder and CEO of Livingspring Family Medical Center, a primary care center located in Mansfield, Texas. She has over 13 years of medical experience. She helps patients live long and well as she believes the quantity of life is just as important as the quality of life. She places emphasis on lifestyle changes that help patients thrive throughout life. Furthermore, Dr. O is a life-enthusiast, a Christian, wife, and mom who enjoys good cuisine and can't get enough of the colors teal and orange.To learn more about Dr O, find her in the following places, and be sure to follow her on Instagram and YouTube in particular!Dr. O has Instagram, Facebook page, TikTok, and LinkedIn accounts. Here is the social media reference where to find Dr. Tolulope Olabintan - https://linktr.ee/drolabintan Also, Dr. O has a YouTube channel where you may watch her collab videos with other doctors and professionals. Please like and share our videos, and subscribe to:  https://www.youtube.com/channel/UCm9LHUGQEBdLV3x_1A_ef7w Lastly, if you are looking for an awesome, thorough, and caring primary care doctor in the Mansfield Texas area, as Dr Olabintan would say “I am she!” Livingspring Family Medical Center is located at 3807 E Broad Street, Suite 101, Mansfield, TX 76063 You may call (817) 717-9597 or go to our website: https://www.livingspringmedicals.com/scheduleReady to learn more about Healing Perfectionism in Women Physicians? See all the details here. CME is available and space is limited, save your seat now. Support the showTo learn more about my coaching practice and group offerings, head over to www.healthierforgood.com. I help Physicians and Allied Health Professional women to let go of toxic perfectionist and people-pleasing habits that leave them frustrated and exhausted. If you are ready to learn skills that help you set boundaries and prioritize yourself, without becoming a cynical a-hole, come work with me.

Bonus Episode: IAS 2023 Conference HighlightsDr. William Short and Dr. Laura Armas-Kolostroubis join Bruce to talk about the research coming out of the 12th IAS Conference on HIV Science that took place July 23-26, 2023. They discuss some of the groundbreaking studies presented at the conference and how the research can be translated into clinical practice. They talk about research on zero transmission, studies looking at the next steps in long-acting technologies, and findings from a clinical trial on the use of statins to prevent cardiovascular disease for those with HIV. They also explore the latest on doxycycline PEP for STI prevention and highlight findings from the ANCHOR study on anal cancer and how to prevent it in people with HIV. About Dr. Short and Dr. Armas-Kolostroubis William R. Short, MD, MPH, AAHIVS, is an Associate Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania. He is also associate director of the HIV Clinical Trial Unit at the University of Pennsylvania and the co-director of the Clinical Core for the Penn Center for AIDS Research. He is chair of the board of directors of the American Academy of HIV Medicine.Laura Armas-Kolostroubis, MD, FACP, AAHIVS, is the founder and CEO of Human Centered Consulting and Care. In clinical practice for more than 20 years, Dr. Armas-Kolostroubis was a practicing physician and Chief Medical Officer at CAN Community Health, and she was a clinical director for the Texas/Oklahoma AIDS Education and Training Center. She sits on the board of directors for the American Academy of HIV Medicine. Resources:IAS 2023, the 12th IAS Conference on HIV Science - https://www.iasociety.org/conferences/ias2023ANCHOR Study - https://anchorstudy.org/REPREIVE Trial - https://www.reprievetrial.org/ ******** Questions about this topic? E-mail podcast@aahivm.org to get connected with Bruce or any of our guests. Are you a medical provider and want to join the conversation? Make your voice heard in the Academy Communities and connect with other HIV clinicians! To learn more about the Academy, visit www.aahivm.org

Welcome to the journey of discovering the keys to living a long and well-rounded life.In one of this week's episodes on Weekly Dose with Dr. Ude, we have a special guest who will share gems on Living long and well. Dr. Tolulpe Olabintan, MD, AAHIVS, FAAFP, DipABLM, is a Board- Certified Family Physician and a fellow of the American Academy of Family Physicians and Board-Certified with the American Board of Lifestyle Medicine. She also completed a Women's Health Fellowship and is a certified HIV specialist by the American Academy of HIV Medicine. She is fondly called by her patients "Dr. O". Dr. O is also the owner and CEO of Livingspring Family Medical Center, a primary care center located in Mansfield, Texas. She has over 13 years of medical experience. She helps patients live long and well as she believes the quantity of life is just as important as the quality of life.Check it out!!Here are the social media links of Dr. Tolulope OlabintanWebsite: https://www.livingspringmedicals.com/scheduleSocial media linksFacebook: Livingspring Family Medical CenterInstagram: dr_olabintanTiktok: dr_olabintanLinkedIn: Tolulope Olabintan MD AAHIVS FAAFP dipABLMYoutube: https://www.livingspringmedicals.com/scheduleLooking for a quality primary-care physician?

Bruce is joined by Dr. Daniel Lee, who discuss HIV-associated weight changes – both gaining and losing weight. First, they examine weight gain in those with HIV and how it can accelerate aging as well as contribute to other diseases, such as hypertension and diabetes. They also discuss losing weight with HIV, although HIV-related weight loss is not as common today as it was in the early days of the HIV epidemic. They emphasize the importance of a healthy diet and maintaining physical activity for people with HIV, especially for those who reduced their activity levels because of the COVID-19 pandemic. About Dr. Daniel Lee:Daniel Lee, MD, AAHIVS, is a clinical professor of medicine at UC San Diego Owen Clinic. He is an HIV primary care provider who has been caring for people with HIV for nearly 25 years. He's also the clinical director for the Pacific AIDS Education Training Center HIV Learning Network, and the Founder and Director of the Owen Lipid/Lipodystrophy Clinic, which is a subspecialty clinic focused on managing metabolic complications of antiretroviral therapy. Resources: CDC Healthy Living with HIV POZ Magazine: Weight Gain and HIV NAM: Weight Gain and HIV Treatment ******** Questions about this topic? E-mail podcast@aahivm.org to get connected with Bruce or any of our guests. Are you a medical provider and want to join the conversation? Make your voice heard in the Academy Communities and connect with other HIV clinicians! To learn more about the Academy, visit www.aahivm.org

Thanes Vanig, MD, AAHIVS, talks with us about advances in the prevention and treatment of HIV. Chief Medical Officer of Spectrum Medical, Dr. Vanig opened his practice in 1998 after graduating Magna Cum Laude as a King's Scholar from Mahidol University Medical School in Thailand, completing his Internal Medicine residency at Harvard Medical School, and receiving his Postdoctoral Fellowship in Infectious Diseases from Stanford University Medical School. Internationally recognized in HIV Medicine, he speaks, publishes, and advises regularly. Dr. Vanig serves on the City of Phoenix Fast Track Cities Initiative and is a leader for the Maricopa START (State of Arizona Rapid Treatment) Program, immediately linking newly diagnosed HIV patients to care. Arizona Physician Podcast is a production of Maricopa County Medical Society. Hosted by John McElligott.

Dr. Donna Sweet and Bruce discuss the history of the HIV epidemic through the lens of Dr. Sweet's personal experience as a practitioner. They talk about the early experiences of treating and managing HIV and AIDS before tests, empirical treatments, and sufficient knowledge about the virus. They discuss how antiretroviral therapy and new clinical case definitions in the 1990s and 2000s allowed for better treatment and management of HIV. Throughout the conversation, they mention how the stigma surrounding HIV and homosexuality remains prevalent and unnecessary and the danger of continuing misinformation. They conclude with an outlook on the future of HIV medicine, vaccinations and cure.  About Dr. Donna Sweet:Donna Sweet, MD, AAHIVS, MACP, is a professor of internal medicine at the University of Kansas School of Medicine in Wichita, Kansas, and has been credentialed with the Academy since its inception. She has an HIV program in her clinic with federal Ryan White, Parts B, C, D and F funds, where she cares for approximately 1,400 patients with HIV. Resources: Timeline of the HIV epidemic - https://www.hiv.gov/hiv-basics/overview/history/hiv-and-aids-timeline  UCSF AIDS History Project Collections - https://www.library.ucsf.edu/archives/aids/collections/ Future directions - https://www.niaid.nih.gov/diseases-conditions/future-hiv-treatment  ******** Questions about this topic? E-mail podcast@aahivm.org to get connected with Bruce or any of our guests. Are you a medical provider and want to join the conversation? Make your voice heard in the Academy Communities and connect with other HIV clinicians! To learn more about the Academy, visit www.aahivm.org

Such a privilege to talk with Dr. Tolulope Olabintan! Take a listen to learn about Gout.Dr. Olabintan always smiles. It is contagious. You cannot be around her and not feel loved and cared for. Her patients love her, and we do too! I had the privilege to interview her on this  episode of UnabridgedMD. I hope you enjoy our interview as much as I need. It's time to live with joy. Dr. Tolulope Olabintan, MD, AAHIVS, FAAFP, DipABLM is a Board-Certified Family Physician and a Fellow of the American Academy of Family Physicians and Board-Certified with American Board of Lifestyle Medicine. She also completed a Women's Health Fellowship and is a certified HIV specialist by the American Academy of HIV Medicine. She is fondly called by her patients as "Dr. O."Dr. O is also the owner and CEO of Livingspring Family Medical Center, a primary care center located in Mansfield, Texas. She has over 13 years of medical experience. She helps patients live long and well as she believes the quantity of life is just as important as the quality of life. She places emphasis on lifestyle changes that help patients thrive throughout life.Furthermore, Dr. O is a life-enthusiast, a Christian, wife, and mom who enjoys good cuisine and can't get enough of the colors teal and orange.WHERE TO REACH DR O:Dr. O has Instagram, Facebook page, TikTok, and LinkedIn accounts. Here is the social media reference where to find Dr. Tolulope Olabintan - https://linktr.ee/drolabintanAlso, Dr. O has a YouTube channel where you may watch her collab videos with other doctors and professionals. Please like and share our videos, and subscribe to https://www.youtube.com/channel/UCm9LHUGQEBdLV3x_1A_ef7w_____________For more information Read our latest blog about GoutLINK: https://www.unabridgedmd.com/post/_goutIf you are in need of a rheumatologist in Colorado, look no further. To schedule an appointment, please email us at info@unabridgedMD.com.#bestrheumatologist #bestrheumatologistinDenver #autoimmunedisease#RheumatologyClinic #JointPain #Arthritis #inflammatory #podcastIf you live in Colorado and are looking for a rheumatologist to help you achieve disease remission, email or contact us at UnabridgedMD.com. We are the first direct care rheumatology in Colorado and can see you within a week!

In this episode, Carolyn Chu, MD, MSc, FAAFP, AAHIVS, discusses using HIV-ASSIST to aid in the selection of an ART regimen for PWH coinfected with HBV and HCV. Listen as she covers:How HIV-ASSIST supports ART selection in primary careUpdates to viral hepatitis recommendations including:               CDC HBV screening and testing recommendations             AASLD simplified HCV treatment approach for PWHHIV-ASSIST for managing HIV/HBV coinfections, including ensuring that NRTIs that are effective for both HIV and HBV are included in an ART regimen and alerting the user when an additional HBV treatment is needed HIV-ASSIST for managing HIV/HCV coinfections, including showing how the HIV-ASSIST tool incorporates drug‒drug interaction considerations from the University of Liverpool HIV Drug Interaction CheckerCarolyn Chu, MD, MSc, FAAFP, AAHIVSChief Clinical OfficerNational Clinician Consultation CenterProfessorClinical Family Community MedicineUniversity of California, San FranciscoSan Francisco, CaliforniaLink to full program: bit.ly/3pwaH2Y    

Bruce is joined by Dr. Hannan Braun to talk about substance use disorder and its overlap with the HIV epidemic. They discuss what a substance use disorder is and the risks of HIV for those who inject illicit substances. They also cover the HIV pre-exposure prophylaxis (PrEP) that is available for those who have a substance use disorder and the benefits for using PrEP. As well, Dr. Braun covers the various options available for treating a substance use disorder and highlights the ways people can recover with successful intervention. He also touches on some of the hurdles that providers face when trying to treat a substance use disorder and some of the ways that providers can help prevent HIV in those who are using substances.  About Dr. BraunHannan Braun, MD, AAHIVS, is an HIV primary care doctor and addiction medicine specialist in the Division of General Internal Medicine at Denver Health in Denver, Colorado. He completed his residency in internal medicine-primary care at Boston Medical Center and a fellowship in addiction medicine at Brown University. His clinical and scholarship interests include low-barrier substance use disorder treatment, HIV prevention for people who use drugs, harm reduction, LGBTQ+ health, and inpatient addiction medicine. Resources:Substance Abuse and Mental Health Services Administration - https://www.samhsa.gov/ CDC: Recovery is For Everyone - https://www.cdc.gov/drugoverdose/featured-topics/recovery-SUD.html HIV.gov: Substance Use Disorders and HIV - https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/substance-use-disorders-and-hiv  ******** Questions about this topic? E-mail podcast@aahivm.org to get connected with Bruce or any of our guests. Are you a medical provider and want to join the conversation? Make your voice heard in the Academy Communities and connect with other HIV clinicians! To learn more about the Academy, visit www.aahivm.org

In this episode, Jona Tanguay, MMSc, PA-C, AAHIVS discusses considerations to review with patients to empower them to make their own informed choices in PrEP selection, including:Leveraging PrEP options with unique dosing schedules and/or routes such as long-acting cabotegravir and on-demand 2-1-1 FTC/TDFDifferences in adverse effect profiles between 4 PrEP optionsPotential for HIV resistanceRequirements for compliance and monitoringEvidence in populations with various acquisition behaviorsDrug interaction implications Faculty: Jona Tanguay, MMSc, PA-C, AAHIVSHealth Care Provider and HIV Specialist Whitman-Walker HealthVice President for Education, GLMA: Health Professionals Advancing LGBTQ EqualityClinical Instructor, Yale University School of Nursing Washington, DC Link to full program: https://bit.ly/41WF54o

This episode, Long-Acting Injectable PrEP and HIV Treatment, is the second in a three-episode series about new evidence-based strategies for addressing HIV and AIDS.Guests featured in this episode:Jeremiah JohnsonProgram ManagerPrep4All Amy Killelea, J.D., Killelea Consulting Aviva Cantor, PA-C, AAHIVS, PhD, Callen-Lorde Community Health CenterModerator: Alexandra Walker, Digital Communications Director, NACHCAlexandra: Hello and welcome to Health Centers on the Frontlines, the podcast of the National Association of Community Health Centers. Today is the second in a three-episode series we're doing about an epidemic that the nation's health centers have been battling for decades: HIV and AIDS. During these episodes, we're sharing promising news about how community health centers, health center controlled networks and primary care associations are employing the latest strategies to link people to ongoing HIV prevention, treatment, and care services. Today, we're happy to be joined by a panel of experts, Jeremiah Johnson, who is the Program Manager at Prep4All, an organization of professionals and patients based in New York City who advocate for greater access to lifesaving medication for HIV. Also joining us is Amy Killelea, JD, an expert in policy, medication access, and health care financing to develop sustainable HIV and Hepatitis programs. And Dr. Aviva Cantor, HIV specialist and primary care provider at Callen-Lorde Community Health Center, which serves New York City's lesbian, gay, bisexual, and transgender communities. So in late 2021, the US public was introduced to a bi-monthly injectable form of PrEP, which stands for Pre-Exposure Prophylaxis. Taken in pill form and now also available as an injectable this medication reduces the chance of getting HIV from sex or injection drug use. When taken as prescribed, PrEP is highly effective for preventing HIV, a landmark push to end the HIV epidemic. At the same time, people living with HIV have been introduced to a monthly injectable form of treatment that similarly puts them in charge of their healthcare needs without having to remind themselves to take a daily oral medication. This is revolutionizing the field of treatment and prevention of HIV because we never have had a form of either that was this long lasting. Also, it's exciting news because it expands the number of tools we have in our hands to fight HIV. Health centers have been taking their first steps in implementing these tools. So, starting with our health center guest. Aviva, can you explain to our audience the two types of injectable antiretroviral medication? We've heard that one can be used as PrEP for people who are HIV negative and the other as an HIV treatment for people who are living with HIV. Can you tell us about the similarities and differences?Aviva: Sure. Yeah. So the two medications and we use brand names here. I normally don't like to use brand names, but we'll use them so that they're more clear for patients in the community. So one is called Cabenuva. That's the medication that's used for HIV treatment. And the other is called Apretude. That is the medication that's used for HIV prevention. What they both have in common are that they are both what I describe to patients and my colleagues as deep intramuscular injections. So they're a little different than your regular intramuscular injections. They have to be done by nurses who have been trained just a little bit differently to make sure they do it the right way. So they're both these deep intramuscular injections. They're actually both now available as bi-monthly or every-two-month injections. They actually sort of follow the same schedule where you're given your initial injection, you're given one one month later as a loading dose, and then you take an injection every two months, every eight weeks, essentially. The big difference between these medications is, first of all, for HIV treatment (Cabenuva), it's two (injections;) it's a combination of two medications. So it's two separate injections, one in each buttock (one medication in each buttock). For HIV treatment, for Apretude, for prevention, it's just the one injection in one buttock.Alexandra: Yeah, that's a good first start. We can get back to some of those issues in more depth. Jeremiah, drawing from your experience as a community member and advocate, what do you think is important for the community health centers that we represent around the country to know and consider as they see these new options for prevention and treatment?Jeremiah: Yeah, happy to talk about that. Thanks for having me on the podcast today. And really, you know, I think, Dr. Cantor, you really set us up really well because I think you clearly have a clear sort of centering of your patients and the way that you're sort of talking about things. Because I think one of the first things that I'll say about long acting injectable is it is exciting. I also, as a community advocate, am very cognizant of the price issue with this, so when you're looking at $22,500 a year for Apretude compared to less than $20 a month for generic TDF FTC (Tenofovir/emtricitabine) or generic Truvada, this is going to be a complicated intervention to get to people. And I do worry as a community advocate, given that there's such important adherence requirements if you're going to be on this, that, you know, community health centers are checking with patients and really making sure that they're not going to run into any sort of unexpected coverage issues or anything that's going to interrupt their ability to continue with their treatment in terms of all of this. And so, you know, one thing that I like to put out there at these sorts of conversations is that, you know, sometimes I think we get really excited about the new modality. We get excited about the new way to sort of put things out there and forget the old classics, you know, and in this case, we have, you know, new sort of access to these generic medications that can be more nimble in a complicated health care system to get to people and we can be more creative in terms of getting that out to people. And so, you know, one thing that we're working a lot here at PrEP4all right now is to try and build a national PrEP program calling for a federal program with centralized reimbursement of laboratory costs and medications, particularly for uninsured and underinsured individualsAlexandra: Thank you. Some really good points there. I want to turn it to Amy. As health centers consider delivering these services, what are the financial or policy hurdles that they need to be aware of?Amy: Yeah. So I think this is a really good question. And, and, you know, the short answer is that there are a lot. So, I think the first one is that, and this has been mentioned several times, the price of the drug and combined with the fact that it is a provider- administered injectable product, so that is just a different administration route than the vast majority of the antiretrovirals that are available right now. And those two things, both apart and combined, do, I think, add some complexity to the finances and the procurement and delivery of both Apretude and Cabenuva. And I'm going to go through some of these challenges and note throughout that the challenges are different depending on what population you're talking about, whether the population is insured or uninsured. So I'm going to try to underscore what some of those differences look like. And, you know, the number one piece and to sort of tie this to specifically for community health centers, so that the price of both drugs was raised, and it is, you know, pretty, it could be higher. Right? But in the grand scheme of things, over $22,000 a year for a list price for an ARV is in the upper threshold of ARVs that are available for HIV treatment and prevention, so it's not an insignificant list price. If we talk about community health centers and their status as 340B entities, there is a discount available to purchase that drug for your uninsured population, and yet even with the discount, the price is still fairly significant. So that's an important factor as community health centers look at budgeting and programmatic decisions on both routes, on both Apretude and Cabenuva. And when we talk about the insured, I think even now when these products have been on the market and available in the case of Apretude for, you know, a little less than a year and for Cabenuva longer than that, we still have sort of complexity challenges and, and murkiness, I would say, with regard to payer behavior for insured clients.You know, on the PrEP side, we don't have a U.S. Preventive Services Task Force grade for long-acting Cabotegravir. The grade A that we have is based on the oral products for PrEP. We are waiting for a USPSTF grade and that would carry with it a requirement that the vast majority of payers cover long-acting Cabotegravir/Apretude without cost sharing.Alexandra: Thank you. Would you like to add to that in terms of considerations that other community health centers who are considering offering these should factor in?Aviva: Yeah, I mean, Amy brought up a lot of things that we are currently dealing with. I present on PrEP and on long-acting medications for PrEP and HIV a lot. And I have this slide (Slide 1) that shows how incredibly excited we are for these medications to be here. And then the next slide (Slide 2) is just total chaos because that's what it feels like. It's sort of like, “Hold up, wait, yes we're excited, but let's be realistic about this.” This is really hard. It's really hard right now. You know, you need the people to do the work, but you also need the fuThis show is part of the Spreaker Prime Network, if you are interested in advertising on this podcast, contact us at https://www.spreaker.com/show/5468540/advertisement

Bruce is joined by Angela Kapalko, PA-C, AAHIVS, to talk about the current state of the HIV Workforce and the needs of the future.  As the generation of providers who started treating HIV at the beginning of the epidemic approach retirement, the need for a new generation of clinicians to care for the now aging population of people with HIV is greater than ever.  Bruce and Angela discuss current trends and needs in the HIV workforce, specifically with regards to Nurse Practitioners and Physician Assistants and their unique role in filling that gap.  They also discuss specific initiatives that are helping to encourage younger practitioners to specialize in HIV care.About Angela Kapalko:Angela has been practicing medicine since 2007, with her entire career in the HIV healthcare space. Her passion is in education of both patients as well as healthcare students and new clinicians. She lectures at a number of Physician Assistant programs throughout the Philadelphia area, hosting students for clinical preceptorships and assisting those who want to continue in the work with future jobs. In 2022, with the help of the academy, she started the PA Preceptorship Program, with the goal of connecting PA students throughout the country with practicing PAs in HIV prevention and medicine for clinical rotations to increase the knowledge and ultimately the workforce for the future. Resources:CDC: HIV Self-Tests - https://www.cdc.gov/hiv/basics/hiv-testing/hiv-self-tests.htmlAAHIVM PA Preceptorship Program - https://aahivm.org/papreceptorship/******** Questions about this topic? E-mail podcast@aahivm.org to get connected with Bruce or any of our guests. Are you a medical provider and want to join the conversation? Make your voice heard in the Academy Communities and connect with other HIV clinicians! To learn more about the Academy, visit www.aahivm.org

Dr. Olabintan always smiles. It is contagious. You cannot be around her and not feel loved and cared for. Her patients love her, and we do too! I had the privilege to interview her on this  episode of UnabridgedMD. I hope you enjoy our interview as much as I need. It's time to live with joy. Dr. Tolulope Olabintan, MD, AAHIVS, FAAFP, DipABLM is a Board-Certified Family Physician and a Fellow of the American Academy of Family Physicians and Board-Certified with American Board of Lifestyle Medicine. She also completed a Women's Health Fellowship and is a certified HIV specialist by the American Academy of HIV Medicine. She is fondly called by her patients as "Dr. O."Dr. O is also the owner and CEO of Livingspring Family Medical Center, a primary care center located in Mansfield, Texas. She has over 13 years of medical experience. She helps patients live long and well as she believes the quantity of life is just as important as the quality of life. She places emphasis on lifestyle changes that help patients thrive throughout life.Furthermore, Dr. O is a life-enthusiast, a Christian, wife, and mom who enjoys good cuisine and can't get enough of the colors teal and orange.WHERE TO REACH DR O:Dr. O has Instagram, Facebook page, TikTok, and LinkedIn accounts. Here is the social media reference where to find Dr. Tolulope Olabintan - https://linktr.ee/drolabintanAlso, Dr. O has a YouTube channel where you may watch her collab videos with other doctors and professionals. Please like and share our videos, and subscribe to https://www.youtube.com/channel/UCm9LHUGQEBdLV3x_1A_ef7wLastly, if you are looking for an awesome, thorough, and caring primary care doctor in the Mansfield area, as Dr Olabintan would say “I am she!”Livingspring Family Medical Center is located at 3807 E Broad Street, Suite 101, Mansfield, TX 76063You may call (817) 717-9597 orGo to our website: https://www.livingspringmedicals.com/schedule______________Our practice UnabridgedMD in Rheumatology is currently accepting new patients! If you are looking for a rheumatologist in Colorado state, contact us at  www.UnabridgedMD.com or Email us at info@unabridgedMD.com to learn more.In health, Isabelle Amigues, MD, MS, RhMSUSCEO and Founder UnabridgedMD.comIf you live in Colorado and are looking for a rheumatologist to help you achieve disease remission, email or contact us at UnabridgedMD.com. We are the first direct care rheumatology in Colorado and can see you within a week!

In this episode, Carolyn Chu, MD, MSc, FAAFP, AAHIVS, and Samantha Strong, PharmD, BCACP, AAHIVP, CDCES, answer questions including:Strategies to improve disparities in pre-exposure prophylaxis (PrEP) access in difficult-to-reach populations Key remaining questions related to PrEP options for cisgender women and people who inject drugsConcerns about resistance at seroconversion in patients with suboptimal PrEP complianceImplementation of molecular screening for patients receiving PrEPExpectations for weight gain and patient counseling pointsPresenters:Carolyn Chu, MD, MSc, FAAFP, AAHIVSChief Medical OfficerAmerican Academy of HIV MedicineChief Clinical OfficerNational Clinician Consultation CenterSamantha Strong, PharmD, BCACP, AAHIVP, CDCES Clinical Director of PharmacyNevada Health CentersLas Vegas, NevadaLink to full program: https://bit.ly/3Fqdgs9

Break the Stigma, Save a Life is part of the Treating Addiction in Primary Care series. M. Shoaib Khan, MD, AAHIVS interviews Sky Lee, MD, AAHIVS and MK Orsulak, MD, MPH, AAHIVS Health care providers may still blame patients for their substance use disorder (SUD) even though we know that addiction is a brain disorder and not the result of moral weakness. This episode dives deep into the origins of SUD stigma and how it merged with racism in the U.S. to influence drug policy and treatment. We'll discuss harm reduction and how to promote health and dignity with people who use drugs. On the Podcast: M. Shoaib Khan, MD, AAHIVS is core faculty at UCSF Fresno with a focus on underserved populations in the San Joaquin Valley area. Sky Lee, MD, AAHIVS works with people who are incarcerated. Previously she was on the faculty of UC Davis Medical Center, and worked with the CA Bridge program. MK Orsulak, MD, MPH, AAHIVS serves patients at the Sacramento County Primary Care Clinic, Mercy Clinic at Loaves and Fishes, and the Sacramento County Department of Public Health Sexual Health Clinic. She is an attending on the inpatient UC Davis Substance Use Intervention Team. Rob Assibey, MD, hosts. For full bios of speakers, please visit: www.familydocs.org/podcast. Resources: CAFP - CA Academy of Family Physicians, Substance Use Disorder: education, resources, projects, and peer support https://familydocs.org/sud NCCC California Substance Use Line: 24/7 confidential provider tele-consultation for SUD https://nccc.ucsf.edu/clinician-consultation/substance-use-management/california-substance-use-line/ 844-326-2626 CA Bridge: training, information, and advocacy across California and beyond https://cabridge.org National Harm Reduction Coalition: to increase access to strategies like overdose prevention and syringe access programs https://harmreduction.org/  Bevel Up: safer use, overdose prevention & other harm reduction tips https://www.bvlup.com/  Thanks: The Family Docs Podcast series Treating Addiction in Primary Care is supported by the National Institute on Drug Abuse (NIDA) and the California Department of Health Care Services (DHCS). Thanks to Shatterproof for sharing ambassador voices. Visit the California Academy of Family Physicians online at www.familydocs.org. Follow us on social media: Twitter - https://twitter.com/cafp_familydocs Instagram - https://www.instagram.com/cafp_familydocs Facebook - https://www.facebook.com/familydocs  

In this episode, Jill Blumenthal, MD, MAS, and William R. Short, MD, MPH, AAHIVS, address key considerations when evaluating ART safety and tolerability in pregnant people, those trying to conceive, and transgender individuals, such as:Approaching patients trying to conceive on nonpreferred ART regimens (eg, 2-drug regimens like LA CAB and RPV)Optimizing the use of the Antiretroviral Pregnancy RegistryAddressing unique barriers to ARV adherence in transgender individuals with HIV (eg, drug formulation considerations for ARV medications and gender-affirming hormone therapy, sperm banking or egg harvesting, drug coverage considerations)Faculty: Jill Blumenthal, MD, MASAssociate Professor of MedicineInfectious Diseases and Global Public Health University of California, San DiegoSan Diego, CaliforniaWilliam R. Short, MD, MPH, AAHIVSAssociate Professor of MedicineDivision of Infectious Diseases Department of Medicine  Perelman School of Medicine at the University of Pennsylvania Philadelphia, PennsylvaniaLink to full program:http://bit.ly/3PM3nYeLink to downloadable slides: http://bit.ly/3WgYycz

In this podcast, Susan LeLacheur, DrPH, PA-C, AAHIVS discusses racial disparities in access to HIV prevention (PrEP) and strategies to close these gaps, including:Incorporating comprehensive sexual history into medical appointments and offering PrEP to all sexually active patientsIncrease awareness of PrEP access programs in communities of colorDiversification of the medical workforceFaculty: Susan LeLacheur, DrPH, PA-C, AAHIVSProfessorDepartment of Physician Assistant StudiesSchool of Medicine and Health SciencesThe George Washington UniversityWashington, DCLink to full program: https://practicingclinicians.com/content/hiv-prevention-resource-center

In this episode, Carolyn Chu, MD, MSc, FAAFP, AAHIVS, discusses improving HIV pre-exposure prophylaxis accessibility and availability for PWID, including by:Integrating PrEP with services that PWID are already aware of and/or connected to (eg, harm reduction/syringe services and substance use disorder treatment programs, peer-based training/education initiatives, healthcare for the homeless programs, and emergency departments) Staffing PrEP programs with people who are trusted by PWID and delivering PrEP in settings where patients feel respected, comfortable, and safe Tailoring prescribing practices and interventions (eg, same-day medication initiation, on-site pharmacies and/or medication storage, and intensive outreach and navigation) to support the care needs of PWIDCarolyn Chu, MD, MSc, FAAFP, AAHIVSChief Medical OfficeAmerican Academy of HIV MedicineSee the full program at: https://bit.ly/3WhbBvZ

In this episode, Annette Haberl, MD, and William R. Short, MD, MPH, AAHIVS, discuss when to consider an ART switch during pregnancy, including:Current DHHS, EACS, WHO, BHIVA, and German/Austrian guidelines for the use of ARVs in pregnancyWhat data and recommendations for the use of ARVs during pregnancy are currently missing from the guidelinesAvailable data on newer ARVs in the ARV pregnancy registryPharmacokinetic data for newer ARVs including BIC/FTC/TAF and LA CAB + RPV in pregnancyRecommendations for 2-drug ART regimens in pregnancyWhat to do when someone becomes pregnant on a newer ART regimen that is not yet recommended by the guidelinesAnnette Haberl, MDPhysicianHead of HIV and WomenHIVCENTER FrankfurtDepartment of Infectious DiseaseHospital of the Johann Wolfgang Goethe UniversityFrankfurt, GermanyWilliam R. Short, MD, MPH, AAHIVSAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicinePerelman School of Medicine at the University of PennsylvaniaPhiladelphia, PennsylvaniaLink to full program:https://bit.ly/3HPu4Lk

Heterosexual women are not the typical demographic that is targeted in HIV research and treatments.  But their risk factors for HIV are different and require unique methods to address.  Bruce and clinical HIV Specialist™ Dr. William R. Short discuss the needs of women and HIV with a focus on women who are pregnant or may become pregnant.        For more information about the Antiretroviral Pregnancy Registry, visit http://www.apregistry.com/.About Dr. Short:William R. Short, MD, MPH, FIDSA, AAHIVS, is an Associate Professor of Medicine with a secondary appointment for Obstetrics and Gynecology at the Perelman School of Medicine at the University of Pennsylvania.  He serves as Associate Director of AIDS Clinical Trials Unit at the University of Pennsylvania and Co-Director of the Clinical Core at the Penn Center for AIDS Research.******** Questions about this topic? E-mail podcast@aahivm.org to get connected with Bruce or any of our guests. Are you a medical provider and want to join the conversation? Make your voice heard in the Academy Communities and connect with other HIV clinicians! To learn more about the Academy, visit www.aahivm.org

In this podcast, Jonathan Appelbaum, MD, FACP, AAHIVS, summarizes the many medical challenges faced by aging people with HIV, including:Underrepresentation of older patients in medical researchConsequences of early experiences in the epidemic such as late HIV diagnosis and low CD4+ cell count nadir, incomplete or short-lived virologic suppression with early regimens, and toxicity associated with early antiretroviral agentsAdded challenges of multimorbidity and psychosocial challenges, especially mental health issues, loneliness, and social isolationThe need to provide care for the aging HIV population using a holistic approach Gaps in the current healthcare system in providing optimal care for aging people with HIVFaculty:Jonathan Appelbaum, MD, FACP, AAHIVSLaurie L. Dozier Jr, MD, Education DirectorProfessor of Internal MedicineChair, Department of Clinical SciencesFlorida State University College of MedicineTallahassee, FloridaLink to full program: https://bit.ly/3KkF4iZ

In this episode, Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS, explores the data and recommendations for HIV postexposure prophylaxis (PEP).Listen as she gives perspectives on:The CDC algorithm for evaluation and treatment of potential HIV exposuresThe CDC guideline preferred and alternative PEP antiretroviral therapy regimensData for the use of the single-tablet regimen bictegravir/emtricitabine/tenofovir alafenamide for PEPRecommended laboratory monitoring with PEPThe initiation of pre-exposure prophylaxis following a course of PEP, when appropriatePresenter:Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVSAssistant Professor of PediatricsDivision of Pediatric Infectious DiseasesPediatric and Adolescent HIV Children's Hospital at MontefiorePediatric Hospital of Albert Einstein College of MedicineBronx, New York Follow along with the slides at:https://bit.ly/3NBVXWNSee the entire program at:https://bit.ly/3fOl0XX

In this episode, Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS, explores key considerations for transgender people with HIV (PWH).Listen as she gives perspectives on:Department of Health and Human Services (DHHS) guideline recommendations for transgender PWHProviding HIV care within a gender-affirmative care model, including discussion of strategies, barriers, and facilitatorsGender-affirmative hormone therapy optionsDrug–drug interaction potential between gender-affirmative hormone therapy and antiretroviral therapyRecommended laboratory monitoring while receiving gender-affirming hormone therapyThe cascade of care for transgender PWH and barriers to engagement and retention in carePresenter:Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVSAssistant Professor of PediatricsDivision of Pediatric Infectious DiseasesPediatric and Adolescent HIV  Children's Hospital at MontefiorePediatric Hospital of Albert Einstein  College of MedicineBronx, New York  Follow along with the slides at:https://bit.ly/3wOdKVoLink to full program:https://bit.ly/3fOl0XX

In this episode, Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS, explores key considerations for choosing antiretroviral therapy (ART) for pediatric patients.Listen as she gives perspectives on:Department of Health and Human Services (DHHS) guideline recommendations for infants at risk for perinatal HIV transmissionDHHS guideline–recommended ART regimens for childrenThe ODYSSEY A and B studies evaluating dolutegravir-based ART in children and adolescentsData for the use of the fixed-dose combination bictegravir/emtricitabine/tenofovir alafenamide in children and adolescentsKey ART and management considerations for adolescents and young adults with HIVPresenter:Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVSAssistant Professor of PediatricsDivision of Pediatric Infectious DiseasesPediatric and Adolescent HIV  Children's Hospital at MontefiorePediatric Hospital of Albert Einstein  College of MedicineBronx, New York  Follow along with the slides at:https://bit.ly/3wMur29Link to full program:https://bit.ly/3fOl0XX 

Go online to PeerView.com/ABJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses best practices for improving screening and treatment of HCV infection in the primary care setting. Upon completion of this activity, participants should be better able to: Apply evidence-based guidelines for screening and evaluating patients for HCV infection in the primary care setting, Implement effective follow-up and counseling for patients upon a confirmed diagnosis of HCV infection, Differentiate currently available medications to treat HCV infection based on safety, efficacy, and recommended usage, Integrate direct-acting antiviral agents into individualized treatment plans for patients with HCV infection in accordance with current guidelines and expert recommendations, Employ a multidisciplinary team-based approach for treating HCV infection, distinguishing among patients who can be managed in the primary care setting versus those requiring linkage to specialist care.

Go online to PeerView.com/ABJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses best practices for improving screening and treatment of HCV infection in the primary care setting. Upon completion of this activity, participants should be better able to: Apply evidence-based guidelines for screening and evaluating patients for HCV infection in the primary care setting, Implement effective follow-up and counseling for patients upon a confirmed diagnosis of HCV infection, Differentiate currently available medications to treat HCV infection based on safety, efficacy, and recommended usage, Integrate direct-acting antiviral agents into individualized treatment plans for patients with HCV infection in accordance with current guidelines and expert recommendations, Employ a multidisciplinary team-based approach for treating HCV infection, distinguishing among patients who can be managed in the primary care setting versus those requiring linkage to specialist care.

Go online to PeerView.com/ABJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses best practices for improving screening and treatment of HCV infection in the primary care setting. Upon completion of this activity, participants should be better able to: Apply evidence-based guidelines for screening and evaluating patients for HCV infection in the primary care setting, Implement effective follow-up and counseling for patients upon a confirmed diagnosis of HCV infection, Differentiate currently available medications to treat HCV infection based on safety, efficacy, and recommended usage, Integrate direct-acting antiviral agents into individualized treatment plans for patients with HCV infection in accordance with current guidelines and expert recommendations, Employ a multidisciplinary team-based approach for treating HCV infection, distinguishing among patients who can be managed in the primary care setting versus those requiring linkage to specialist care.

Go online to PeerView.com/ABJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses best practices for improving screening and treatment of HCV infection in the primary care setting. Upon completion of this activity, participants should be better able to: Apply evidence-based guidelines for screening and evaluating patients for HCV infection in the primary care setting, Implement effective follow-up and counseling for patients upon a confirmed diagnosis of HCV infection, Differentiate currently available medications to treat HCV infection based on safety, efficacy, and recommended usage, Integrate direct-acting antiviral agents into individualized treatment plans for patients with HCV infection in accordance with current guidelines and expert recommendations, Employ a multidisciplinary team-based approach for treating HCV infection, distinguishing among patients who can be managed in the primary care setting versus those requiring linkage to specialist care.

Go online to PeerView.com/ABJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses best practices for improving screening and treatment of HCV infection in the primary care setting. Upon completion of this activity, participants should be better able to: Apply evidence-based guidelines for screening and evaluating patients for HCV infection in the primary care setting, Implement effective follow-up and counseling for patients upon a confirmed diagnosis of HCV infection, Differentiate currently available medications to treat HCV infection based on safety, efficacy, and recommended usage, Integrate direct-acting antiviral agents into individualized treatment plans for patients with HCV infection in accordance with current guidelines and expert recommendations, Employ a multidisciplinary team-based approach for treating HCV infection, distinguishing among patients who can be managed in the primary care setting versus those requiring linkage to specialist care.

Go online to PeerView.com/ABJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses best practices for improving screening and treatment of HCV infection in the primary care setting. Upon completion of this activity, participants should be better able to: Apply evidence-based guidelines for screening and evaluating patients for HCV infection in the primary care setting, Implement effective follow-up and counseling for patients upon a confirmed diagnosis of HCV infection, Differentiate currently available medications to treat HCV infection based on safety, efficacy, and recommended usage, Integrate direct-acting antiviral agents into individualized treatment plans for patients with HCV infection in accordance with current guidelines and expert recommendations, Employ a multidisciplinary team-based approach for treating HCV infection, distinguishing among patients who can be managed in the primary care setting versus those requiring linkage to specialist care.

Go online to PeerView.com/ABJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses best practices for improving screening and treatment of HCV infection in the primary care setting. Upon completion of this activity, participants should be better able to: Apply evidence-based guidelines for screening and evaluating patients for HCV infection in the primary care setting, Implement effective follow-up and counseling for patients upon a confirmed diagnosis of HCV infection, Differentiate currently available medications to treat HCV infection based on safety, efficacy, and recommended usage, Integrate direct-acting antiviral agents into individualized treatment plans for patients with HCV infection in accordance with current guidelines and expert recommendations, Employ a multidisciplinary team-based approach for treating HCV infection, distinguishing among patients who can be managed in the primary care setting versus those requiring linkage to specialist care.

Go online to PeerView.com/ABJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses best practices for improving screening and treatment of HCV infection in the primary care setting. Upon completion of this activity, participants should be better able to: Apply evidence-based guidelines for screening and evaluating patients for HCV infection in the primary care setting, Implement effective follow-up and counseling for patients upon a confirmed diagnosis of HCV infection, Differentiate currently available medications to treat HCV infection based on safety, efficacy, and recommended usage, Integrate direct-acting antiviral agents into individualized treatment plans for patients with HCV infection in accordance with current guidelines and expert recommendations, Employ a multidisciplinary team-based approach for treating HCV infection, distinguishing among patients who can be managed in the primary care setting versus those requiring linkage to specialist care.

Tune in to hear our hosts Nicki Shorr and Jessie Swain talk with infection preventionists Rachel Guran and Kelsi Canavan along with Dr. Paula Eckardt about containing a carbapenem-resistant Acinetobacter baumannii complex outbreak in a COVID-19 intensive care unit. With special guests: Rachel Guran, MPH, BSN, RN, CIC, Kelsi Canavan, MPH, MPA, CIC and Paula A. Eckardt, MD, FACP, FIDSA, AAHIVS

In this episode from the series “Key Decisions in HIV Care,” Cristina Mussini, MD, and William R. Short, MD, MPH, AAHIVS, discuss novel therapies for HIV prevention and treatment, including: PreventionCabotegravir for pre-exposure prophylaxis (PrEP) with the latest results from the HPTN 083 and HPTN 084 studiesNovel PrEP therapies in development, including islatravir and lenacapavirInitial therapyLenacapavir for initial therapy with results from the CALIBRATE studySwitch strategiesCabotegravir as a switch strategy with the latest results from the ATLAS-2M study, evaluating Q4W vs Q8W dosing, data on direct-to-inject without the oral lead-in, and data to date in pregnancyHeavily treatment–experienced patientsCurrently available novel therapies for heavily treatment–experienced patients, including fostemsavir and ibalizumabLenacapavir for heavily treatment–experienced patients with results from the CAPELLA studyPresenters:Cristina Mussini, MDHead of Department of Infectious Diseases and Tropical MedicineFull Professor of Infectious DiseasesInfectious Diseases Clinics, University HospitalUniversity of Modena and Reggio EmiliaReggio Emilia, Italy William R. Short, MD, MPH, AAHIVSAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicinePerelman School of Medicine at the University of PennsylvaniaPhiladelphia, Pennsylvania Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.Follow along with the slides at:https://bit.ly/3vWhjHjLink to full program:https://bit.ly/3fOl0XX

In this episode from the series “Key Decisions in HIV Care,” Cristina Mussini, MD, and William R. Short, MD, MPH, AAHIVS, discuss important considerations for ART with opportunistic infections, including: When to start ART with pneumocystis pneumonia including discussion of the ACTG 5164 study of immediate vs delayed ART with opportunistic infectionsEACS, DHHS, and IAS-USA guideline recommendations for starting ART in the setting of most opportunistic infectionsConsiderations for the administration of ART to patients who are unable to swallow or critically ill and intubatedTreatment of Kaposi sarcoma and considerations for starting ART to avoid drug–drug interactions with Kaposi sarcoma treatmentConsiderations for starting ART with cytomegalovirus and the risk for IRIS from cytomegalovirusDiscussion of treatment of cytomegalovirus and overlapping toxicities between its treatment and ARTWhen to start ART with cryptococcal meningitis and the data to support delayed treatment initiation with this particular opportunistic infectionEACS, DHHS, and IAS-USA guideline recommendations for starting ART in the setting of cryptococcal meningitis specificallyTreatment of cryptococcal meningitis and managing drug–drug interactions between ART and antifungal therapyPresenters:Cristina Mussini, MDHead of Department of Infectious Diseases and Tropical MedicineFull Professor of Infectious DiseasesInfectious Diseases Clinics University HospitalUniversity of Modena and Reggio EmiliaReggio Emilia, Italy William R. Short, MD, MPH, AAHIVSAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicinePerelman School of Medicine at the University of PennsylvaniaPhiladelphia, Pennsylvania Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.Follow along with the slides at:https://bit.ly/3uktrm1Link to full program:https://bit.ly/3q2DlGd

In this episode, Jeffrey Kwong, DNP, MPH, FAANP, FAAN, and Susan LeLacheur, DrPH, PA-C, AAHIVS, share insights on new HIV data from CROI 2022, including:Perinatal antiretroviral therapy exposureInvestigational formulation of long-acting contraception combined with pre-exposure prophylaxisMonitoring with long-acting cabotegravir for pre-exposure prophylaxisMyocardial infarction risk by HIV statusPresenters:Jeffrey Kwong, DNP, MPH, FAANP, FAANProfessorDivision of Advanced Nursing PracticeRutgers School of NursingNewark, New JerseyNurse PractitionerGotham Medical GroupNew York, New YorkSusan LeLacheur, DrPH, PA-C, AAHIVSProfessorPA StudiesThe George Washington University School of Medicine and Health SciencesWashington, DCLink to full program:  https://bit.ly/3tdkXfJ

Go online to PeerView.com/WXQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in infectious diseases discusses using telehealth to provide care to patients with HIV. Upon completion of this CE activity, participants should be better able to: Discuss how telehealth is transforming access to quality care and treatment for people with HIV during the coronavirus pandemic, Outline the telehealth technical resources available to manage patients living with HIV, Identify opportunities and strategies to leverage existing resources and infrastructure development to support the extension/utilization of telehealth, services by the healthcare team to provide HIV care.

Go online to PeerView.com/WXQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in infectious diseases discusses using telehealth to provide care to patients with HIV. Upon completion of this CE activity, participants should be better able to: Discuss how telehealth is transforming access to quality care and treatment for people with HIV during the coronavirus pandemic, Outline the telehealth technical resources available to manage patients living with HIV, Identify opportunities and strategies to leverage existing resources and infrastructure development to support the extension/utilization of telehealth, services by the healthcare team to provide HIV care.

Go online to PeerView.com/WXQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in infectious diseases discusses using telehealth to provide care to patients with HIV. Upon completion of this CE activity, participants should be better able to: Discuss how telehealth is transforming access to quality care and treatment for people with HIV during the coronavirus pandemic, Outline the telehealth technical resources available to manage patients living with HIV, Identify opportunities and strategies to leverage existing resources and infrastructure development to support the extension/utilization of telehealth, services by the healthcare team to provide HIV care.

Go online to PeerView.com/WXQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in infectious diseases discusses using telehealth to provide care to patients with HIV. Upon completion of this CE activity, participants should be better able to: Discuss how telehealth is transforming access to quality care and treatment for people with HIV during the coronavirus pandemic, Outline the telehealth technical resources available to manage patients living with HIV, Identify opportunities and strategies to leverage existing resources and infrastructure development to support the extension/utilization of telehealth, services by the healthcare team to provide HIV care.

Go online to PeerView.com/WXQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in infectious diseases discusses using telehealth to provide care to patients with HIV. Upon completion of this CE activity, participants should be better able to: Discuss how telehealth is transforming access to quality care and treatment for people with HIV during the coronavirus pandemic, Outline the telehealth technical resources available to manage patients living with HIV, Identify opportunities and strategies to leverage existing resources and infrastructure development to support the extension/utilization of telehealth, services by the healthcare team to provide HIV care.

Go online to PeerView.com/WXQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in infectious diseases discusses using telehealth to provide care to patients with HIV. Upon completion of this CE activity, participants should be better able to: Discuss how telehealth is transforming access to quality care and treatment for people with HIV during the coronavirus pandemic, Outline the telehealth technical resources available to manage patients living with HIV, Identify opportunities and strategies to leverage existing resources and infrastructure development to support the extension/utilization of telehealth, services by the healthcare team to provide HIV care.

Go online to PeerView.com/WXQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in infectious diseases discusses using telehealth to provide care to patients with HIV. Upon completion of this CE activity, participants should be better able to: Discuss how telehealth is transforming access to quality care and treatment for people with HIV during the coronavirus pandemic, Outline the telehealth technical resources available to manage patients living with HIV, Identify opportunities and strategies to leverage existing resources and infrastructure development to support the extension/utilization of telehealth, services by the healthcare team to provide HIV care.

Go online to PeerView.com/WXQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in infectious diseases discusses using telehealth to provide care to patients with HIV. Upon completion of this CE activity, participants should be better able to: Discuss how telehealth is transforming access to quality care and treatment for people with HIV during the coronavirus pandemic, Outline the telehealth technical resources available to manage patients living with HIV, Identify opportunities and strategies to leverage existing resources and infrastructure development to support the extension/utilization of telehealth, services by the healthcare team to provide HIV care.

In this episode from the series “Key Decisions in HIV Care,” Jonathan Appelbaum, MD, FACP, AAHIVS, and Jens D. Lundgren, MD, DMSc, discuss important considerations for antiretroviral therapy (ART) use in older patients with renal and hepatic impairment.European AIDS Clinical Society guideline screening recommendations for kidney disease in people with HIVAntiretroviral dose adjustment recommendations based on estimated glomerular filtration rateData on the use of full-dose lamivudine with renal impairmentData on the use of 2-drug nucleos(t)ide reverse-transcriptase inhibitor–sparing ART regimens, including GEMINI-1 and -2, TANGO, and SALSA for dolutegravir/lamivudine; SWORD-1 and -2 for dolutegravir/lamivudine; and ATLAS and FLAIR for long-acting cabotegravir plus rilpivirineUS Department of Health and Human Services recommendations on the use of ART agents with hepatic impairmentRecommendations from the American Gastroenterological Association on screening and diagnosis of nonalcoholic fatty liver disease (NAFLD)Prevalence of NAFLD, nonalcoholic steatohepatitis, and liver fibrosis in people with HIVOverlapping risk factors between HIV and NAFLDPresenters:Jonathan Appelbaum, MD, FACP, AAHIVSLaurie L. Dozier Jr, MD, Education DirectorProfessor of Internal MedicineChair, Department of Clinical SciencesFlorida State University College of MedicineTallahassee, Florida Jens D. Lundgren, MD, DMScProfessorRigshospital, University of CopenhagenDirectorCentre of Excellence for Health, Immunity and Infection (CHIP)Rigshospital, University of CopenhagenCopenhagen, Denmark Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.Follow along with the slides at:https://bit.ly/3gAsu19Link to full program:https://bit.ly/3fOl0XX

In this episode from the series “Key Decisions in HIV Care,” Jonathan Appelbaum, MD, FACP, AAHIVS, and Jens D. Lundgren, MD, DMSc, discuss important considerations for ART use in older PWH, including:DHHS, EACS, IAS, and WHO recommendations for first-line ARTVirologic outcomes for older PWH in clinical trials and results from the HealthHIV Second Annual National SurveyPolypharmacy and its potential consequences, including common non-ARV medications prescribed in the VACS cohort, drug–drug interactions with common concomitant medications, common comorbidities in older PWH, and drug–disease state interactions including renal and hepatic impairmentCardiovascular risk considerations including data from the D:A:D study and RESPOND cohort and lipid changes in the TANGO study of switching to DTG/3TC from TAF-based ARTPresenters:Jonathan Appelbaum, MD, FACP, AAHIVSLaurie L. Dozier Jr, MD, Education DirectorProfessor of Internal Medicine  Chair, Department of Clinical SciencesFlorida State University College of MedicineTallahassee, Florida  Jens D. Lundgren, MD, DMScProfessorRigshospital, University of CopenhagenCopenhagen, DenmarkDirectorCentre of Excellence for Health, Immunity and Infection (CHIP)Rigshospital, University of CopenhagenCopenhagen, Denmark  Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.Follow along with the slides at:https://bit.ly/3miT6qHSee the entire program at: https://bit.ly/2TXTYWx 

In this episode, William R. Short, MD, MPH, AAHIVS, explores recommendations and data on strategies to address suboptimal CD4+ cell count response in people with HIV on suppressive ART.Listen as he gives his perspectives on:The consequences of suboptimal CD4+ cell count responseART intensificationART switch strategies with data from the SPIRAL studyData on the addition of interleukin-2 from the SILCAAT and ESPIRIT studiesDHHS guideline recommendationsPresenter:William R. Short, MD, MPH, AAHIVSAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicinePerelman School of Medicine at the University of PennsylvaniaPhiladelphia, PennsylvaniaFollow along with the slides at: https://bit.ly/3DC2bkPSee the entire program at: https://bit.ly/2TXTYWx

In this episode, William R. Short, MD, MPH, AAHIVS, explores recommendations and data on switching to 2-drug single-tablet ART regimens.Listen as he gives his perspectives on:Indications for the available 2-drug single-tablet regimens: DTG/RPV and DTG/3TCThe SWORD-1 and SWORD-2 studies evaluating switching to DTG/RPV in virologically suppressed patientsReal-world experience with switching to DTG/RPV from the OPERA studyThe TANGO study evaluating switching to DTG/3TC from a stable TAF-based ART regimenThe SALSA study evaluating switching to DTG/3TC from any stable 3-drug ART regimenPresenter:William R. Short, MD, MPH, AAHIVSAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicinePerelman School of Medicine at the University of PennsylvaniaPhiladelphia, PennsylvaniaFollow along with the slides at:https://bit.ly/3n0Z8wUSee the entire program at:https://bit.ly/2TXTYWx

INTRODUCTIONThis is an accredited continuing education series of four (4) podcasts as downloadable audio files (MP3).  These podcasts will be released quarterly throughout 2021 and will feature patient testimonial along with their physician to discuss today's patient concerns.    Launch Date: October 14, 2021  ACPE Release Date: October 14, 2021  Expiration Date: September 30, 2022 FACULTY BIOAnthony Martinez, MD, AAHIVS, FAASLDAssociate Professor of MedicineJacobs School of MedicineUniversity at BuffaloMedical Director, Hepatology Erie County Medical CenterBuffalo, NY This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://bit.ly/2QC8Wjq

INTRODUCTIONThis is an accredited continuing education series of four (4) podcasts as downloadable audio files (MP3).  These podcasts will be released throughout 2021 and feature a patient testimonial along with their physician discussing today's patient concerns.    Launch Date: September 7, 2021  Release Date: September 6, 2021   Expiration Date: August 31, 2022 FACULTY BIOAnthony Martinez, MD, AAHIVS, FAASLDAssociate Professor of MedicineJacobs School of MedicineUniversity at BuffaloMedical Director, Hepatology Erie County Medical CenterBuffalo, NY This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://bit.ly/2QC8Wjq

INTRODUCTIONThis is an accredited continuing education series of four (4) podcasts as downloadable audio files (MP3).  These podcasts will be released throughout 2021 and feature a patient testimonial along with their physician discussing today's patient concerns.    Launch Date: July 13, 2021  Release Date: July 13, 2021   Expiration Date: June 30, 2022 FACULTY BIOAnthony Martinez, MD, AAHIVS, FAASLDAssociate Professor of MedicineJacobs School of MedicineUniversity at BuffaloMedical Director, Hepatology Erie County Medical CenterBuffalo, NY This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://bit.ly/2QC8Wjq

In this episode, host Lina Forrestal talks to Dr. Tolulope Olabintan all about her experiences as a mom of two and practicing physician. Dr. Tolu is Board-Certified Family Physician and a Fellow of the American Academy of Family Physicians. With over 13 years of medical experience, she leads the team at Livingspring Family Medical Center, a primary care center located in Mansfield, Texas. Tolulope is also a mom, wife, and Christian. Topics discussed in this episode:Dr. Tolu's birth story: her experience with PPROM (premature rupture of membranes), being admitted to the hospital at 24 weeks and finally giving birth at 34 weeksDr. Tolu's experience with post partum anxiety and Lina's post partum anxietyHow faith and Christianity helped support Dr. Tolu during her post partum depressionHow new moms can take care of their mental health during the newborn phaseHow a new mom recognize the difference between post-partum depression and the baby blues What a couple can do to help maintain a healthy relationship during the newborn phaseNavigating friendships and finding your mom community in the newborn stageWhat inspired Dr. Tolu to take the leap and open her own practiceLearn more about Livingspring Medical. Livingspring was coined from the bible describing God as “The Living Spring” and the ultimate source of true healing. In the place of service, Dr. Olabintan believes she is a conduit of such healing in an atmosphere of compassion, committed care, and with her sound medical knowledge. Connect with Dr. Tolu on Instagram: @dr_olabintanConnect with Lina:Personal Instagram: @linaforrestalBlog: www.linaforrestal.comPodcast Instagram: @newmamaspodcastClubhouse Username: @newmamaspodcastArtwork Credit: Gabi's MediaSupport the show (https://paypal.me/linaforrestal?locale.x=en_US)

INTRODUCTIONThis educational podcast will focus on the initial hepatitis C diagnosis and the challenges the patient faces when interacting with their healthcare provider.Launch Date: May 24, 2021ACPE Release Date: April 26, 2021  Expiration Date: April 30, 2022 ACTIVITY DESCRIPTIONIn this CE podcast series, Dr. Anthony Martinez will discuss his patient's life experience with HCV infection, including diagnosis, interactions with healthcare providers, top treatment concerns, and how life changed since being cured. The series will also discuss approaches to improve HCV outcomes based on lessons learned from these patient perspectives. FACULTY BIOAnthony Martinez, MD, AAHIVS, FAASLDAssociate Professor of MedicineJacobs School of MedicineUniversity at BuffaloMedical Director, Hepatology Erie County Medical CenterBuffalo, NYThis podcast provides accredited continuing education credits. To qualify for credit, please visit https://bit.ly/2QC8Wjq and read all accreditation information at this link prior to listening to this episode.  

Can you believe that the world’s worst outbreak of HIV happened in a rural community in Southern Indiana? In this episode of Rural Health Leadership Radio, we continue the conversation with Dr. Will Cooke, who shares his story of being the sole practitioner in this rural community challenged with this incredible healthcare issue. “We had threats to my life, people threatened to burn down the clinic, there was a lot of pushback” ~Will Cooke William Cooke, MD, FAAFP, FASAM, AAHIVS, is a fellow of the American Academy of Family Medicine and the American Society of Addiction Medicine, specializing in family medicine, addiction medicine, and HIV medicine. His work has been covered by CBS, NBC, PBS, the BBC, USA Today, the New York Times, NPR, and others. In 2019, Dr. Cooke was named National Physician of the Year by the American Academy of Family Physicians and joined the ranks of two US surgeons general and a former secretary of the US Department of Health and Human Services in receiving the Ryan White Distinguished Leadership Award. He was also the first physician to be awarded the Pillar of Excellence by Addiction Policy Forum. Dr. Cooke lives in his hometown of New Albany, Indiana, with his wife, Melissa, and six children. Learn more at: www.canaryinthecoalminebook.com

In this episode, William R. Short, MD, MPH, AAHIVS, discusses current guidelines and clinical trial data informing optimal selection of first-line antiretroviral therapy for HIV.William R. Short, MD, MPH, AAHIVSAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of Medicine  Perelman School of Medicine at the University of PennsylvaniaPhiladelphia, PennsylvaniaContent based on a CME program supported by an independent educational grant from ViiV Healthcare.Link to full program:https://bit.ly/3ux6FF8

What would you do if you were the lone physician living and practicing in a forgotten rural community while facing the world’s worst outbreak of HIV? Would you believe this actually happened in a rural community in Southern Indiana? Hear Dr. Will Cooke’s story about his roller coaster of emotions and challenges that he experienced as he dealt with this hidden epidemic. “The circumstances into which someone is born and raised has a lot to do with their health outcomes.” ~Will Cooke William Cooke, MD, FAAFP, FASAM, AAHIVS, is a fellow of the American Academy of Family Medicine and the American Society of Addiction Medicine, specializing in family medicine, addiction medicine, and HIV medicine. His work has been covered by CBS, NBC, PBS, the BBC, USA Today, the New York Times, NPR, and others. In 2019, Dr. Cooke was named National Physician of the Year by the American Academy of Family Physicians and joined the ranks of two US surgeons general and a former secretary of the US Department of Health and Human Services in receiving the Ryan White Distinguished Leadership Award. He was also the first physician to be awarded the Pillar of Excellence by Addiction Policy Forum. Dr. Cooke lives in his hometown of New Albany, Indiana, with his wife, Melissa, and six children. Learn more at: www.canaryinthecoalminebook.com

In this Episode, Dr. Tyler Evans, Chief Medical Officer of Emergency Management who works on COVID19 response updates us on COIVD19 in NYC. He tells us why did he chose to work in the epicenter of COVID19 in the US and shares his experiences abroad as a physician and public health epxert.  Tyler B. Evans, MD, MS, MPH, AAHIVS, DTM&H currently serves as the Chief Medical Officer (CMO) for the NYC Office of Emergency Management medical section focusing on the COVID-19 response. He was previously the CMO for the county of Santa Cruz (California) Health Services Agency, as well as other CMO posts in Southern California focusing on homelessness, substance abuse and migrant health, as well as leading infectious disease divisions in a number of organizations across the US – including the AIDS HealthCare Foundation. Dr. Evans has held positions with a number of international organizations as well, including Medecins Sans Frontieres/Doctors without Borders (MSF), Physicians for Human Rights (PHR), UNICEF and Partners in Health (PIH) – mostly in sub-Saharan Africa, South Asia and the Middle East.

Go online to PeerView.com/BDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. No single prevention method or approach can stop the HIV epidemic on its own. Several interventions have proved highly effective in reducing the risk of, and protecting against, HIV infection, including male and female condoms, the use of antiretroviral medicines as pre-exposure prophylaxis (PrEP), and the treatment of people living with HIV, to reduce viral load and prevent onward transmission. Despite the availability of this widening array of effective HIV prevention tools and a massive scale-up of HIV treatment in recent years, new infections among adults globally have not decreased sufficiently, and infections have actually increased in the United States among African American gay and bisexual men and Hispanic/Latino gay and bisexual men. Although the Centers for Disease Control and Prevention has issued clinical practice guidelines for PrEP use in the United States, numerous implementation barriers remain, including questions about the effectiveness of PrEP, optimal settings for provision, cost, and the most effective ways to motivate healthcare practitioners to prescribe PrEP. Protocols to identify individuals who are most likely to benefit from PrEP have been developed, but addressing racial, ethnic, and socioeconomic disparities poses additional challenges. This activity will marry Dr. Donna Sweet's personal experiences in clinical utilization of HIV prevention strategies with practical, evidence-based guidance for patient care decisions, to provide additional motivation and rationale for participants to review their own current management strategies and adjust them as needed to optimize patient care. Upon completion of this activity, participants will be able to: Effectively engage patients in conversations about sexual health practice, to assess HIV risk factors and support their ability to have healthy sex lives, Develop comprehensive competencies (with a focus on pre-exposure prophylaxis [PrEP] interventions) based on a provider's individual patient needs, Consider current evidence and individual patient needs/preferences when integrating HIV prevention options (eg, PrEP, post-exposure prophylaxis [PEP], viral suppression, female condoms) into clinical practice, Employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among patients at increased risk for HIV infection, Facilitate access to HIV prevention options by effectively connecting patients to available resources, support, and assistance, Describe currently available tools that have been shown to significantly reduce the risk of HIV transmission or acquisition

Go online to PeerView.com/BDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. No single prevention method or approach can stop the HIV epidemic on its own. Several interventions have proved highly effective in reducing the risk of, and protecting against, HIV infection, including male and female condoms, the use of antiretroviral medicines as pre-exposure prophylaxis (PrEP), and the treatment of people living with HIV, to reduce viral load and prevent onward transmission. Despite the availability of this widening array of effective HIV prevention tools and a massive scale-up of HIV treatment in recent years, new infections among adults globally have not decreased sufficiently, and infections have actually increased in the United States among African American gay and bisexual men and Hispanic/Latino gay and bisexual men. Although the Centers for Disease Control and Prevention has issued clinical practice guidelines for PrEP use in the United States, numerous implementation barriers remain, including questions about the effectiveness of PrEP, optimal settings for provision, cost, and the most effective ways to motivate healthcare practitioners to prescribe PrEP. Protocols to identify individuals who are most likely to benefit from PrEP have been developed, but addressing racial, ethnic, and socioeconomic disparities poses additional challenges. This activity will marry Dr. Donna Sweet's personal experiences in clinical utilization of HIV prevention strategies with practical, evidence-based guidance for patient care decisions, to provide additional motivation and rationale for participants to review their own current management strategies and adjust them as needed to optimize patient care. Upon completion of this activity, participants will be able to: Effectively engage patients in conversations about sexual health practice, to assess HIV risk factors and support their ability to have healthy sex lives, Develop comprehensive competencies (with a focus on pre-exposure prophylaxis [PrEP] interventions) based on a provider's individual patient needs, Consider current evidence and individual patient needs/preferences when integrating HIV prevention options (eg, PrEP, post-exposure prophylaxis [PEP], viral suppression, female condoms) into clinical practice, Employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among patients at increased risk for HIV infection, Facilitate access to HIV prevention options by effectively connecting patients to available resources, support, and assistance, Describe currently available tools that have been shown to significantly reduce the risk of HIV transmission or acquisition

Go online to PeerView.com/BDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. No single prevention method or approach can stop the HIV epidemic on its own. Several interventions have proved highly effective in reducing the risk of, and protecting against, HIV infection, including male and female condoms, the use of antiretroviral medicines as pre-exposure prophylaxis (PrEP), and the treatment of people living with HIV, to reduce viral load and prevent onward transmission. Despite the availability of this widening array of effective HIV prevention tools and a massive scale-up of HIV treatment in recent years, new infections among adults globally have not decreased sufficiently, and infections have actually increased in the United States among African American gay and bisexual men and Hispanic/Latino gay and bisexual men. Although the Centers for Disease Control and Prevention has issued clinical practice guidelines for PrEP use in the United States, numerous implementation barriers remain, including questions about the effectiveness of PrEP, optimal settings for provision, cost, and the most effective ways to motivate healthcare practitioners to prescribe PrEP. Protocols to identify individuals who are most likely to benefit from PrEP have been developed, but addressing racial, ethnic, and socioeconomic disparities poses additional challenges. This activity will marry Dr. Donna Sweet's personal experiences in clinical utilization of HIV prevention strategies with practical, evidence-based guidance for patient care decisions, to provide additional motivation and rationale for participants to review their own current management strategies and adjust them as needed to optimize patient care. Upon completion of this activity, participants will be able to: Effectively engage patients in conversations about sexual health practice, to assess HIV risk factors and support their ability to have healthy sex lives, Develop comprehensive competencies (with a focus on pre-exposure prophylaxis [PrEP] interventions) based on a provider's individual patient needs, Consider current evidence and individual patient needs/preferences when integrating HIV prevention options (eg, PrEP, post-exposure prophylaxis [PEP], viral suppression, female condoms) into clinical practice, Employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among patients at increased risk for HIV infection, Facilitate access to HIV prevention options by effectively connecting patients to available resources, support, and assistance, Describe currently available tools that have been shown to significantly reduce the risk of HIV transmission or acquisition

Go online to PeerView.com/BDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. No single prevention method or approach can stop the HIV epidemic on its own. Several interventions have proved highly effective in reducing the risk of, and protecting against, HIV infection, including male and female condoms, the use of antiretroviral medicines as pre-exposure prophylaxis (PrEP), and the treatment of people living with HIV, to reduce viral load and prevent onward transmission. Despite the availability of this widening array of effective HIV prevention tools and a massive scale-up of HIV treatment in recent years, new infections among adults globally have not decreased sufficiently, and infections have actually increased in the United States among African American gay and bisexual men and Hispanic/Latino gay and bisexual men. Although the Centers for Disease Control and Prevention has issued clinical practice guidelines for PrEP use in the United States, numerous implementation barriers remain, including questions about the effectiveness of PrEP, optimal settings for provision, cost, and the most effective ways to motivate healthcare practitioners to prescribe PrEP. Protocols to identify individuals who are most likely to benefit from PrEP have been developed, but addressing racial, ethnic, and socioeconomic disparities poses additional challenges. This activity will marry Dr. Donna Sweet's personal experiences in clinical utilization of HIV prevention strategies with practical, evidence-based guidance for patient care decisions, to provide additional motivation and rationale for participants to review their own current management strategies and adjust them as needed to optimize patient care. Upon completion of this activity, participants will be able to: Effectively engage patients in conversations about sexual health practice, to assess HIV risk factors and support their ability to have healthy sex lives, Develop comprehensive competencies (with a focus on pre-exposure prophylaxis [PrEP] interventions) based on a provider's individual patient needs, Consider current evidence and individual patient needs/preferences when integrating HIV prevention options (eg, PrEP, post-exposure prophylaxis [PEP], viral suppression, female condoms) into clinical practice, Employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among patients at increased risk for HIV infection, Facilitate access to HIV prevention options by effectively connecting patients to available resources, support, and assistance, Describe currently available tools that have been shown to significantly reduce the risk of HIV transmission or acquisition

Go online to PeerView.com/BDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. No single prevention method or approach can stop the HIV epidemic on its own. Several interventions have proved highly effective in reducing the risk of, and protecting against, HIV infection, including male and female condoms, the use of antiretroviral medicines as pre-exposure prophylaxis (PrEP), and the treatment of people living with HIV, to reduce viral load and prevent onward transmission. Despite the availability of this widening array of effective HIV prevention tools and a massive scale-up of HIV treatment in recent years, new infections among adults globally have not decreased sufficiently, and infections have actually increased in the United States among African American gay and bisexual men and Hispanic/Latino gay and bisexual men. Although the Centers for Disease Control and Prevention has issued clinical practice guidelines for PrEP use in the United States, numerous implementation barriers remain, including questions about the effectiveness of PrEP, optimal settings for provision, cost, and the most effective ways to motivate healthcare practitioners to prescribe PrEP. Protocols to identify individuals who are most likely to benefit from PrEP have been developed, but addressing racial, ethnic, and socioeconomic disparities poses additional challenges. This activity will marry Dr. Donna Sweet's personal experiences in clinical utilization of HIV prevention strategies with practical, evidence-based guidance for patient care decisions, to provide additional motivation and rationale for participants to review their own current management strategies and adjust them as needed to optimize patient care. Upon completion of this activity, participants will be able to: Effectively engage patients in conversations about sexual health practice, to assess HIV risk factors and support their ability to have healthy sex lives, Develop comprehensive competencies (with a focus on pre-exposure prophylaxis [PrEP] interventions) based on a provider's individual patient needs, Consider current evidence and individual patient needs/preferences when integrating HIV prevention options (eg, PrEP, post-exposure prophylaxis [PEP], viral suppression, female condoms) into clinical practice, Employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among patients at increased risk for HIV infection, Facilitate access to HIV prevention options by effectively connecting patients to available resources, support, and assistance, Describe currently available tools that have been shown to significantly reduce the risk of HIV transmission or acquisition

Go online to PeerView.com/BDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. No single prevention method or approach can stop the HIV epidemic on its own. Several interventions have proved highly effective in reducing the risk of, and protecting against, HIV infection, including male and female condoms, the use of antiretroviral medicines as pre-exposure prophylaxis (PrEP), and the treatment of people living with HIV, to reduce viral load and prevent onward transmission. Despite the availability of this widening array of effective HIV prevention tools and a massive scale-up of HIV treatment in recent years, new infections among adults globally have not decreased sufficiently, and infections have actually increased in the United States among African American gay and bisexual men and Hispanic/Latino gay and bisexual men. Although the Centers for Disease Control and Prevention has issued clinical practice guidelines for PrEP use in the United States, numerous implementation barriers remain, including questions about the effectiveness of PrEP, optimal settings for provision, cost, and the most effective ways to motivate healthcare practitioners to prescribe PrEP. Protocols to identify individuals who are most likely to benefit from PrEP have been developed, but addressing racial, ethnic, and socioeconomic disparities poses additional challenges. This activity will marry Dr. Donna Sweet's personal experiences in clinical utilization of HIV prevention strategies with practical, evidence-based guidance for patient care decisions, to provide additional motivation and rationale for participants to review their own current management strategies and adjust them as needed to optimize patient care. Upon completion of this activity, participants will be able to: Effectively engage patients in conversations about sexual health practice, to assess HIV risk factors and support their ability to have healthy sex lives, Develop comprehensive competencies (with a focus on pre-exposure prophylaxis [PrEP] interventions) based on a provider's individual patient needs, Consider current evidence and individual patient needs/preferences when integrating HIV prevention options (eg, PrEP, post-exposure prophylaxis [PEP], viral suppression, female condoms) into clinical practice, Employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among patients at increased risk for HIV infection, Facilitate access to HIV prevention options by effectively connecting patients to available resources, support, and assistance, Describe currently available tools that have been shown to significantly reduce the risk of HIV transmission or acquisition

Go online to PeerView.com/BDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. No single prevention method or approach can stop the HIV epidemic on its own. Several interventions have proved highly effective in reducing the risk of, and protecting against, HIV infection, including male and female condoms, the use of antiretroviral medicines as pre-exposure prophylaxis (PrEP), and the treatment of people living with HIV, to reduce viral load and prevent onward transmission. Despite the availability of this widening array of effective HIV prevention tools and a massive scale-up of HIV treatment in recent years, new infections among adults globally have not decreased sufficiently, and infections have actually increased in the United States among African American gay and bisexual men and Hispanic/Latino gay and bisexual men. Although the Centers for Disease Control and Prevention has issued clinical practice guidelines for PrEP use in the United States, numerous implementation barriers remain, including questions about the effectiveness of PrEP, optimal settings for provision, cost, and the most effective ways to motivate healthcare practitioners to prescribe PrEP. Protocols to identify individuals who are most likely to benefit from PrEP have been developed, but addressing racial, ethnic, and socioeconomic disparities poses additional challenges. This activity will marry Dr. Donna Sweet's personal experiences in clinical utilization of HIV prevention strategies with practical, evidence-based guidance for patient care decisions, to provide additional motivation and rationale for participants to review their own current management strategies and adjust them as needed to optimize patient care. Upon completion of this activity, participants will be able to: Effectively engage patients in conversations about sexual health practice, to assess HIV risk factors and support their ability to have healthy sex lives, Develop comprehensive competencies (with a focus on pre-exposure prophylaxis [PrEP] interventions) based on a provider's individual patient needs, Consider current evidence and individual patient needs/preferences when integrating HIV prevention options (eg, PrEP, post-exposure prophylaxis [PEP], viral suppression, female condoms) into clinical practice, Employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among patients at increased risk for HIV infection, Facilitate access to HIV prevention options by effectively connecting patients to available resources, support, and assistance, Describe currently available tools that have been shown to significantly reduce the risk of HIV transmission or acquisition

Go online to PeerView.com/BDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. No single prevention method or approach can stop the HIV epidemic on its own. Several interventions have proved highly effective in reducing the risk of, and protecting against, HIV infection, including male and female condoms, the use of antiretroviral medicines as pre-exposure prophylaxis (PrEP), and the treatment of people living with HIV, to reduce viral load and prevent onward transmission. Despite the availability of this widening array of effective HIV prevention tools and a massive scale-up of HIV treatment in recent years, new infections among adults globally have not decreased sufficiently, and infections have actually increased in the United States among African American gay and bisexual men and Hispanic/Latino gay and bisexual men. Although the Centers for Disease Control and Prevention has issued clinical practice guidelines for PrEP use in the United States, numerous implementation barriers remain, including questions about the effectiveness of PrEP, optimal settings for provision, cost, and the most effective ways to motivate healthcare practitioners to prescribe PrEP. Protocols to identify individuals who are most likely to benefit from PrEP have been developed, but addressing racial, ethnic, and socioeconomic disparities poses additional challenges. This activity will marry Dr. Donna Sweet's personal experiences in clinical utilization of HIV prevention strategies with practical, evidence-based guidance for patient care decisions, to provide additional motivation and rationale for participants to review their own current management strategies and adjust them as needed to optimize patient care. Upon completion of this activity, participants will be able to: Effectively engage patients in conversations about sexual health practice, to assess HIV risk factors and support their ability to have healthy sex lives, Develop comprehensive competencies (with a focus on pre-exposure prophylaxis [PrEP] interventions) based on a provider's individual patient needs, Consider current evidence and individual patient needs/preferences when integrating HIV prevention options (eg, PrEP, post-exposure prophylaxis [PEP], viral suppression, female condoms) into clinical practice, Employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among patients at increased risk for HIV infection, Facilitate access to HIV prevention options by effectively connecting patients to available resources, support, and assistance, Describe currently available tools that have been shown to significantly reduce the risk of HIV transmission or acquisition

Go online to PeerView.com/VQJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. No single prevention method or approach can stop the HIV epidemic on its own. Several interventions have proved highly effective in reducing the risk of, and protecting against, HIV infection, including male and female condoms, the use of antiretroviral medicines as pre-exposure prophylaxis (PrEP), and the treatment of people living with HIV, to reduce viral load and prevent onward transmission. Despite the availability of this widening array of effective HIV prevention tools and a massive scale-up of HIV treatment in recent years, new infections among adults globally have not decreased sufficiently, and infections have actually increased in the United States among African American gay and bisexual men and Hispanic/Latino gay and bisexual men. Although the Centers for Disease Control and Prevention has issued clinical practice guidelines for PrEP use in the United States, numerous implementation barriers remain, including questions about the effectiveness of PrEP, optimal settings for provision, cost, and the most effective ways to motivate healthcare practitioners to prescribe PrEP. Protocols to identify individuals who are most likely to benefit from PrEP have been developed, but addressing racial, ethnic, and socioeconomic disparities poses additional challenges. This activity will marry Dr. Donna Sweet's personal experiences in clinical utilization of HIV prevention strategies with practical, evidence-based guidance for patient care decisions, to provide additional motivation and rationale for participants to review their own current management strategies and adjust them as needed to optimize patient care. Upon completion of this CE activity, participants will be able to: Effectively engage clients in conversations about sexual health practices to assess HIV risk factors and support their ability to have healthy sex lives, Develop a set of comprehensive competencies (with a focus on PrEP interventions) based on a provider's individual client needs, Apply current evidence with individual client needs/preferences when integrating HIV prevention options (eg, PrEP, PEP, viral suppression, female condoms) into practice, Employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among clients at increased risk for HIV infection, Facilitate access to HIV prevention options by effectively connecting clients to available resources, support, and assistance, Describe currently available and emerging tools that have been shown to significantly reduce the risk of HIV transmission or acquisition, Describe currently available methods for client-friendly diagnostic tests that measure and improve adherence to medications.

Go online to PeerView.com/VQJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. No single prevention method or approach can stop the HIV epidemic on its own. Several interventions have proved highly effective in reducing the risk of, and protecting against, HIV infection, including male and female condoms, the use of antiretroviral medicines as pre-exposure prophylaxis (PrEP), and the treatment of people living with HIV, to reduce viral load and prevent onward transmission. Despite the availability of this widening array of effective HIV prevention tools and a massive scale-up of HIV treatment in recent years, new infections among adults globally have not decreased sufficiently, and infections have actually increased in the United States among African American gay and bisexual men and Hispanic/Latino gay and bisexual men. Although the Centers for Disease Control and Prevention has issued clinical practice guidelines for PrEP use in the United States, numerous implementation barriers remain, including questions about the effectiveness of PrEP, optimal settings for provision, cost, and the most effective ways to motivate healthcare practitioners to prescribe PrEP. Protocols to identify individuals who are most likely to benefit from PrEP have been developed, but addressing racial, ethnic, and socioeconomic disparities poses additional challenges. This activity will marry Dr. Donna Sweet's personal experiences in clinical utilization of HIV prevention strategies with practical, evidence-based guidance for patient care decisions, to provide additional motivation and rationale for participants to review their own current management strategies and adjust them as needed to optimize patient care. Upon completion of this CE activity, participants will be able to: Effectively engage clients in conversations about sexual health practices to assess HIV risk factors and support their ability to have healthy sex lives, Develop a set of comprehensive competencies (with a focus on PrEP interventions) based on a provider's individual client needs, Apply current evidence with individual client needs/preferences when integrating HIV prevention options (eg, PrEP, PEP, viral suppression, female condoms) into practice, Employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among clients at increased risk for HIV infection, Facilitate access to HIV prevention options by effectively connecting clients to available resources, support, and assistance, Describe currently available and emerging tools that have been shown to significantly reduce the risk of HIV transmission or acquisition, Describe currently available methods for client-friendly diagnostic tests that measure and improve adherence to medications.

Go online to PeerView.com/VQJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. No single prevention method or approach can stop the HIV epidemic on its own. Several interventions have proved highly effective in reducing the risk of, and protecting against, HIV infection, including male and female condoms, the use of antiretroviral medicines as pre-exposure prophylaxis (PrEP), and the treatment of people living with HIV, to reduce viral load and prevent onward transmission. Despite the availability of this widening array of effective HIV prevention tools and a massive scale-up of HIV treatment in recent years, new infections among adults globally have not decreased sufficiently, and infections have actually increased in the United States among African American gay and bisexual men and Hispanic/Latino gay and bisexual men. Although the Centers for Disease Control and Prevention has issued clinical practice guidelines for PrEP use in the United States, numerous implementation barriers remain, including questions about the effectiveness of PrEP, optimal settings for provision, cost, and the most effective ways to motivate healthcare practitioners to prescribe PrEP. Protocols to identify individuals who are most likely to benefit from PrEP have been developed, but addressing racial, ethnic, and socioeconomic disparities poses additional challenges. This activity will marry Dr. Donna Sweet's personal experiences in clinical utilization of HIV prevention strategies with practical, evidence-based guidance for patient care decisions, to provide additional motivation and rationale for participants to review their own current management strategies and adjust them as needed to optimize patient care. Upon completion of this CE activity, participants will be able to: Effectively engage clients in conversations about sexual health practices to assess HIV risk factors and support their ability to have healthy sex lives, Develop a set of comprehensive competencies (with a focus on PrEP interventions) based on a provider's individual client needs, Apply current evidence with individual client needs/preferences when integrating HIV prevention options (eg, PrEP, PEP, viral suppression, female condoms) into practice, Employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among clients at increased risk for HIV infection, Facilitate access to HIV prevention options by effectively connecting clients to available resources, support, and assistance, Describe currently available and emerging tools that have been shown to significantly reduce the risk of HIV transmission or acquisition, Describe currently available methods for client-friendly diagnostic tests that measure and improve adherence to medications.

Go online to PeerView.com/VQJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. No single prevention method or approach can stop the HIV epidemic on its own. Several interventions have proved highly effective in reducing the risk of, and protecting against, HIV infection, including male and female condoms, the use of antiretroviral medicines as pre-exposure prophylaxis (PrEP), and the treatment of people living with HIV, to reduce viral load and prevent onward transmission. Despite the availability of this widening array of effective HIV prevention tools and a massive scale-up of HIV treatment in recent years, new infections among adults globally have not decreased sufficiently, and infections have actually increased in the United States among African American gay and bisexual men and Hispanic/Latino gay and bisexual men. Although the Centers for Disease Control and Prevention has issued clinical practice guidelines for PrEP use in the United States, numerous implementation barriers remain, including questions about the effectiveness of PrEP, optimal settings for provision, cost, and the most effective ways to motivate healthcare practitioners to prescribe PrEP. Protocols to identify individuals who are most likely to benefit from PrEP have been developed, but addressing racial, ethnic, and socioeconomic disparities poses additional challenges. This activity will marry Dr. Donna Sweet's personal experiences in clinical utilization of HIV prevention strategies with practical, evidence-based guidance for patient care decisions, to provide additional motivation and rationale for participants to review their own current management strategies and adjust them as needed to optimize patient care. Upon completion of this CE activity, participants will be able to: Effectively engage clients in conversations about sexual health practices to assess HIV risk factors and support their ability to have healthy sex lives, Develop a set of comprehensive competencies (with a focus on PrEP interventions) based on a provider's individual client needs, Apply current evidence with individual client needs/preferences when integrating HIV prevention options (eg, PrEP, PEP, viral suppression, female condoms) into practice, Employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among clients at increased risk for HIV infection, Facilitate access to HIV prevention options by effectively connecting clients to available resources, support, and assistance, Describe currently available and emerging tools that have been shown to significantly reduce the risk of HIV transmission or acquisition, Describe currently available methods for client-friendly diagnostic tests that measure and improve adherence to medications.

Go online to PeerView.com/VQJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. No single prevention method or approach can stop the HIV epidemic on its own. Several interventions have proved highly effective in reducing the risk of, and protecting against, HIV infection, including male and female condoms, the use of antiretroviral medicines as pre-exposure prophylaxis (PrEP), and the treatment of people living with HIV, to reduce viral load and prevent onward transmission. Despite the availability of this widening array of effective HIV prevention tools and a massive scale-up of HIV treatment in recent years, new infections among adults globally have not decreased sufficiently, and infections have actually increased in the United States among African American gay and bisexual men and Hispanic/Latino gay and bisexual men. Although the Centers for Disease Control and Prevention has issued clinical practice guidelines for PrEP use in the United States, numerous implementation barriers remain, including questions about the effectiveness of PrEP, optimal settings for provision, cost, and the most effective ways to motivate healthcare practitioners to prescribe PrEP. Protocols to identify individuals who are most likely to benefit from PrEP have been developed, but addressing racial, ethnic, and socioeconomic disparities poses additional challenges. This activity will marry Dr. Donna Sweet's personal experiences in clinical utilization of HIV prevention strategies with practical, evidence-based guidance for patient care decisions, to provide additional motivation and rationale for participants to review their own current management strategies and adjust them as needed to optimize patient care. Upon completion of this CE activity, participants will be able to: Effectively engage clients in conversations about sexual health practices to assess HIV risk factors and support their ability to have healthy sex lives, Develop a set of comprehensive competencies (with a focus on PrEP interventions) based on a provider's individual client needs, Apply current evidence with individual client needs/preferences when integrating HIV prevention options (eg, PrEP, PEP, viral suppression, female condoms) into practice, Employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among clients at increased risk for HIV infection, Facilitate access to HIV prevention options by effectively connecting clients to available resources, support, and assistance, Describe currently available and emerging tools that have been shown to significantly reduce the risk of HIV transmission or acquisition, Describe currently available methods for client-friendly diagnostic tests that measure and improve adherence to medications.

Go online to PeerView.com/VQJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. No single prevention method or approach can stop the HIV epidemic on its own. Several interventions have proved highly effective in reducing the risk of, and protecting against, HIV infection, including male and female condoms, the use of antiretroviral medicines as pre-exposure prophylaxis (PrEP), and the treatment of people living with HIV, to reduce viral load and prevent onward transmission. Despite the availability of this widening array of effective HIV prevention tools and a massive scale-up of HIV treatment in recent years, new infections among adults globally have not decreased sufficiently, and infections have actually increased in the United States among African American gay and bisexual men and Hispanic/Latino gay and bisexual men. Although the Centers for Disease Control and Prevention has issued clinical practice guidelines for PrEP use in the United States, numerous implementation barriers remain, including questions about the effectiveness of PrEP, optimal settings for provision, cost, and the most effective ways to motivate healthcare practitioners to prescribe PrEP. Protocols to identify individuals who are most likely to benefit from PrEP have been developed, but addressing racial, ethnic, and socioeconomic disparities poses additional challenges. This activity will marry Dr. Donna Sweet's personal experiences in clinical utilization of HIV prevention strategies with practical, evidence-based guidance for patient care decisions, to provide additional motivation and rationale for participants to review their own current management strategies and adjust them as needed to optimize patient care. Upon completion of this CE activity, participants will be able to: Effectively engage clients in conversations about sexual health practices to assess HIV risk factors and support their ability to have healthy sex lives, Develop a set of comprehensive competencies (with a focus on PrEP interventions) based on a provider's individual client needs, Apply current evidence with individual client needs/preferences when integrating HIV prevention options (eg, PrEP, PEP, viral suppression, female condoms) into practice, Employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among clients at increased risk for HIV infection, Facilitate access to HIV prevention options by effectively connecting clients to available resources, support, and assistance, Describe currently available and emerging tools that have been shown to significantly reduce the risk of HIV transmission or acquisition, Describe currently available methods for client-friendly diagnostic tests that measure and improve adherence to medications.

Go online to PeerView.com/VQJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. No single prevention method or approach can stop the HIV epidemic on its own. Several interventions have proved highly effective in reducing the risk of, and protecting against, HIV infection, including male and female condoms, the use of antiretroviral medicines as pre-exposure prophylaxis (PrEP), and the treatment of people living with HIV, to reduce viral load and prevent onward transmission. Despite the availability of this widening array of effective HIV prevention tools and a massive scale-up of HIV treatment in recent years, new infections among adults globally have not decreased sufficiently, and infections have actually increased in the United States among African American gay and bisexual men and Hispanic/Latino gay and bisexual men. Although the Centers for Disease Control and Prevention has issued clinical practice guidelines for PrEP use in the United States, numerous implementation barriers remain, including questions about the effectiveness of PrEP, optimal settings for provision, cost, and the most effective ways to motivate healthcare practitioners to prescribe PrEP. Protocols to identify individuals who are most likely to benefit from PrEP have been developed, but addressing racial, ethnic, and socioeconomic disparities poses additional challenges. This activity will marry Dr. Donna Sweet's personal experiences in clinical utilization of HIV prevention strategies with practical, evidence-based guidance for patient care decisions, to provide additional motivation and rationale for participants to review their own current management strategies and adjust them as needed to optimize patient care. Upon completion of this CE activity, participants will be able to: Effectively engage clients in conversations about sexual health practices to assess HIV risk factors and support their ability to have healthy sex lives, Develop a set of comprehensive competencies (with a focus on PrEP interventions) based on a provider's individual client needs, Apply current evidence with individual client needs/preferences when integrating HIV prevention options (eg, PrEP, PEP, viral suppression, female condoms) into practice, Employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among clients at increased risk for HIV infection, Facilitate access to HIV prevention options by effectively connecting clients to available resources, support, and assistance, Describe currently available and emerging tools that have been shown to significantly reduce the risk of HIV transmission or acquisition, Describe currently available methods for client-friendly diagnostic tests that measure and improve adherence to medications.

Go online to PeerView.com/VQJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. No single prevention method or approach can stop the HIV epidemic on its own. Several interventions have proved highly effective in reducing the risk of, and protecting against, HIV infection, including male and female condoms, the use of antiretroviral medicines as pre-exposure prophylaxis (PrEP), and the treatment of people living with HIV, to reduce viral load and prevent onward transmission. Despite the availability of this widening array of effective HIV prevention tools and a massive scale-up of HIV treatment in recent years, new infections among adults globally have not decreased sufficiently, and infections have actually increased in the United States among African American gay and bisexual men and Hispanic/Latino gay and bisexual men. Although the Centers for Disease Control and Prevention has issued clinical practice guidelines for PrEP use in the United States, numerous implementation barriers remain, including questions about the effectiveness of PrEP, optimal settings for provision, cost, and the most effective ways to motivate healthcare practitioners to prescribe PrEP. Protocols to identify individuals who are most likely to benefit from PrEP have been developed, but addressing racial, ethnic, and socioeconomic disparities poses additional challenges. This activity will marry Dr. Donna Sweet's personal experiences in clinical utilization of HIV prevention strategies with practical, evidence-based guidance for patient care decisions, to provide additional motivation and rationale for participants to review their own current management strategies and adjust them as needed to optimize patient care. Upon completion of this CE activity, participants will be able to: Effectively engage clients in conversations about sexual health practices to assess HIV risk factors and support their ability to have healthy sex lives, Develop a set of comprehensive competencies (with a focus on PrEP interventions) based on a provider's individual client needs, Apply current evidence with individual client needs/preferences when integrating HIV prevention options (eg, PrEP, PEP, viral suppression, female condoms) into practice, Employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among clients at increased risk for HIV infection, Facilitate access to HIV prevention options by effectively connecting clients to available resources, support, and assistance, Describe currently available and emerging tools that have been shown to significantly reduce the risk of HIV transmission or acquisition, Describe currently available methods for client-friendly diagnostic tests that measure and improve adherence to medications.